South Africa Unresectable Hepatocellular Carcinoma Market Analysis

South Africa Unresectable Hepatocellular Carcinoma Market Analysis


$ 3999

South Africa Unresectable Hepatocellular Carcinoma Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Unresectable Hepatocellular Carcinoma market is growing globally due to the increasing incidence of unresectable hepatocellular carcinoma which is mainly due to rise in risk factors such as chronic hepatitis B and C infections, alcohol abuse, non-alcoholic fatty liver disease (NAFLD), and obesity. Advancements in diagnostic techniques like imaging techniques and biopsy, introduction of targeted therapies, immunotherapies, rising emphasis on combination therapies, clinical Trials and research initiatives. Bayer AG, Bristol Myers Squibb Company, Eisai Co., Ltd., Exelixis, Inc., Ipsen Pharma, Merck & Co., Inc., Novartis International AG, Roche Holding AG, Sanofi S.A., Takeda Pharmaceutical Company Limited are the key global market players in unresectable hepatocellular carcinoma market.

ID: IN10ZAPH416 CATEGORY: Pharmaceuticals GEOGRAPHY: South Africa AUTHOR: Dr. Netal Patel

Buy Now

South Africa Unresectable Hepatocellular Carcinoma Market Analysis Summary

South Africa Unresectable Hepatocellular Carcinoma Market is valued at around $12.6 Mn in 2022 and is projected to reach $14.9 Mn by 2030, exhibiting a CAGR of 2.07% during the forecast period 2023-2030.

Hepatocellular carcinoma (HCC) that cannot be physically removed is referred to as unresectable HCC. This is because of things like the tumor's size, location, or extension, or because there is an underlying liver condition. It is a difficult and aggressive type of cancer that needs specialized treatment methods to control the condition and enhance patient results. A multidisciplinary strategy may combine systemic medicines, locoregional therapies, and supportive care in the treatment of unresectable HCC. The main objectives of treatment are to reduce symptoms, extend survival, control tumor growth, and enhance quality of life. Systemic therapies like targeted therapies including drugs like sorafenib lenvatinib, regorafenib, immune checkpoint inhibitors like nivolumab, and in locoregional therapy transarterial chemoembolization, etc are used. Sorafenib has the highest revenue share. Bayer AG, Bristol Myers Squibb Company, Eisai Co., Ltd., Exelixis, Inc., Ipsen Pharma, Merck & Co., Inc., Novartis International AG, Roche Holding AG, Sanofi S.A., Takeda Pharmaceutical Company Limited are the key global market players in unresectable hepatocellular carcinoma market.

Market Dynamics

Market Growth Drivers

The increasing incidence of unresectable hepatocellular carcinoma is mainly due to a rise in risk factors such as chronic hepatitis B and C infections, alcohol abuse, non-alcoholic fatty liver disease (NAFLD), and obesity. Advancements in diagnostic techniques like imaging techniques and biopsy, the introduction of targeted therapies, and immunotherapies, rising emphasis on combination therapies, clinical trials, and research initiatives act as market growth drivers.

Market Restraints

Limited treatment options, high cost of treatment, adverse side effects associated with therapies, resistance, and disease progression, diagnosis and awareness challenges, and regulatory and reimbursement hurdles act as market growth restraints.     

Competitive Landscape

Key Player

  • Bayer AG
  • Bristol Myers Squibb Company
  • Eisai Co., Ltd.
  • Exelixis, Inc.
  • Ipsen Pharma
  • Merck & Co., Inc.
  • Novartis International AG
  • Roche Holding AG
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Market Segmentations For South Africa Unresectable Hepatocellular Carcinoma Market

By Treatment Type

  • Systemic Therapies
  • Locoregional Therapies
  • Supportive Care

By Mode of Administration

  • Oral Medications
  • Intravenous Infusion
  • Intra-arterial or Localized Delivery

By End Users

  • Hospitals
  • Cancer Centers
  • Clinics and Ambulatory Surgical Centers

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


Last updated on: 27 February 2024
Updated by: Dhruv Joshi

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up